| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
59 A decade of amyloid PET imaging: advances in neuroinflammation
|
Nordberg, Agneta
|
|
2012
|
33 |
S1 |
p. S26-
1 p.
|
artikel
|
| 2 |
47 AFFITOPE®-based vaccines: A novel and safe immunotherapeutic strategy for neurodegenerative diseases
|
Mandler, Markus
|
|
2012
|
33 |
S1 |
p. S20-S21
2 p.
|
artikel
|
| 3 |
70 AFFITOPE® — based vaccines: results from phase I support the further clinical development of AFFITOPE® AD02
|
Schneeberger, Achim
|
|
2012
|
33 |
S1 |
p. S30-S31
2 p.
|
artikel
|
| 4 |
52 Alzheimer's disease: what have we learned and where must we go?
|
Morris, John C.
|
|
2012
|
33 |
S1 |
p. S23-
1 p.
|
artikel
|
| 5 |
85 Alzheimer therapy: present and future
|
Winblad, Bengt
|
|
2012
|
33 |
S1 |
p. S36-S37
2 p.
|
artikel
|
| 6 |
86 Animal models for preclinical testing of early AD?
|
Windisch, Manfred
|
|
2012
|
33 |
S1 |
p. S37-
1 p.
|
artikel
|
| 7 |
35 Antibody therapy of Alzheimer's disease
|
Hock, Christoph
|
|
2012
|
33 |
S1 |
p. S16-
1 p.
|
artikel
|
| 8 |
89 Anti-oxidants in Alzheimer's disease and MCI
|
Zekry, Dina
|
|
2012
|
33 |
S1 |
p. S38-
1 p.
|
artikel
|
| 9 |
49 Aβ oligomers as diagnostic and therapeutic targets for Alzheimer's disease
|
Masters, Colin
|
|
2012
|
33 |
S1 |
p. S21-S22
2 p.
|
artikel
|
| 10 |
44 ApoE-directed therapeutics for the treatment of Alzheimer's disease
|
Landreth, Gary
|
|
2012
|
33 |
S1 |
p. S19-
1 p.
|
artikel
|
| 11 |
51 ApoE4 potentiates the amyloid cascade and inhibits neuroprotective mechanisms: prevention of these effects by DHA diet
|
Michaelson, Daniel M.
|
|
2012
|
33 |
S1 |
p. S22-S23
2 p.
|
artikel
|
| 12 |
67 A regulatory viewpoint
|
Sampaio, Cristina
|
|
2012
|
33 |
S1 |
p. S29-S30
2 p.
|
artikel
|
| 13 |
71 Are we ready to perform clinical trials in early AD patients? which patients, which outcomes?
|
Schneider, Lon S.
|
|
2012
|
33 |
S1 |
p. S31-
1 p.
|
artikel
|
| 14 |
5 Are we ready with a new trial design?
|
Becker, Robert E.
|
|
2012
|
33 |
S1 |
p. S3-
1 p.
|
artikel
|
| 15 |
45 Astrocyte-neuron metabolic coupling in Alzheimer's disease
|
Magistretti, Pierre
|
|
2012
|
33 |
S1 |
p. S20-
1 p.
|
artikel
|
| 16 |
Author Index
|
|
|
2012
|
33 |
S1 |
p. S39-S40
2 p.
|
artikel
|
| 17 |
76 Beneficial effect of anti APP antibodies on Alzheimer's pathology
|
Solomon, Beka
|
|
2012
|
33 |
S1 |
p. S33-
1 p.
|
artikel
|
| 18 |
66 Brain imaging in early detection of Alzheimer's disease and other dementias
|
Rowe, Christopher C.
|
|
2012
|
33 |
S1 |
p. S29-
1 p.
|
artikel
|
| 19 |
80 Caring for people with dementia
|
Trabucchi, Marco
|
|
2012
|
33 |
S1 |
p. S34-S35
2 p.
|
artikel
|
| 20 |
17 Cell therapy with nerve growth factor (NGF) in Alzheimer's disease
|
Eriksdotter, Maria
|
|
2012
|
33 |
S1 |
p. S8-
1 p.
|
artikel
|
| 21 |
68 Cerebral microbleeds: identification, prevalence and clinical relevance
|
Scheltens, Philip
|
|
2012
|
33 |
S1 |
p. S30-
1 p.
|
artikel
|
| 22 |
32 Cerebral microinfarcts: A key target in vascular cognitive impairment?
|
Gold, Gabriel
|
|
2012
|
33 |
S1 |
p. S14-
1 p.
|
artikel
|
| 23 |
38 Chinese early-onset familial Alzheimer's disease
|
Jia, Jianping
|
|
2012
|
33 |
S1 |
p. S17-
1 p.
|
artikel
|
| 24 |
55 Cholinergic and amyloid activity in prodromal AD: implications for disease treatment
|
Mufson, Elliott
|
|
2012
|
33 |
S1 |
p. S24-
1 p.
|
artikel
|
| 25 |
34 Cognitive reserve and survival
|
Herrmann, François R.
|
|
2012
|
33 |
S1 |
p. S15-S16
2 p.
|
artikel
|
| 26 |
21 Concomitant activation of G-protein coupled receptors (GPCR) and sigma1 receptor (Sig1R): a novel pharmacological concept in treatment of Alzheimer's disease (AD)
|
Fisher, Abraham
|
|
2012
|
33 |
S1 |
p. S10-
1 p.
|
artikel
|
| 27 |
Contents
|
|
|
2012
|
33 |
S1 |
p. v-ix
nvt p.
|
artikel
|
| 28 |
Contents
|
|
|
2012
|
33 |
S1 |
p. OBC-
1 p.
|
artikel
|
| 29 |
64 CSF sample acquisition and analyses for translational research purposes
|
Riordan, Henry J.
|
|
2012
|
33 |
S1 |
p. S28-
1 p.
|
artikel
|
| 30 |
74 Disease-modification in mild cognitive impairment by lowering homocysteine
|
Smith, A. David
|
|
2012
|
33 |
S1 |
p. S32-
1 p.
|
artikel
|
| 31 |
11 Early clinical development of amyloid-beta specific PET radioligand [18F]AZD4694
|
Cselényi, Zsolt
|
|
2012
|
33 |
S1 |
p. S5-S6
2 p.
|
artikel
|
| 32 |
50 Early diagnosis for Lewy body disease and treatment
|
Mckeith, Ian G.
|
|
2012
|
33 |
S1 |
p. S22-
1 p.
|
artikel
|
| 33 |
Editorial Advisory Board
|
|
|
2012
|
33 |
S1 |
p. IFC-
1 p.
|
artikel
|
| 34 |
31 EEG-based prediction of rapid cognitive decline in MCI
|
Giannakopoulos, Panteleimon
|
|
2012
|
33 |
S1 |
p. S14-
1 p.
|
artikel
|
| 35 |
36 Effect of Anti-ApoE antibodies on Aβ pathology and accumulation
|
Kim, J.
|
|
2012
|
33 |
S1 |
p. S16-
1 p.
|
artikel
|
| 36 |
58 EoFAD: imaging and genetics
|
Nordberg, Agneta
|
|
2012
|
33 |
S1 |
p. S25-
1 p.
|
artikel
|
| 37 |
27 EOFAD: Opportunities for proof-of-concept studies to modify disease progresssion
|
Gauthier, Serge
|
|
2012
|
33 |
S1 |
p. S12-
1 p.
|
artikel
|
| 38 |
53 EoFAD: update on dominantly inherited Alzheimer network (DIAN)
|
Morris, John C.
|
|
2012
|
33 |
S1 |
p. S23-
1 p.
|
artikel
|
| 39 |
3 Evidence in humans linking a specific amyloid-β oligomer to tau pathobiology
|
Handoko, M.
|
|
2012
|
33 |
S1 |
p. S2-
1 p.
|
artikel
|
| 40 |
63 Following drug effects with PET imaging markers
|
Rinne, Juha
|
|
2012
|
33 |
S1 |
p. S27-S28
2 p.
|
artikel
|
| 41 |
39 Fronto-temporal degeneraton, an update
|
Kertesz, Andrew
|
|
2012
|
33 |
S1 |
p. S17-S18
2 p.
|
artikel
|
| 42 |
82 Getting to grips with water-soluble brain-derived Aβ dimers
|
Walsh, Dominic
|
|
2012
|
33 |
S1 |
p. S35-S36
2 p.
|
artikel
|
| 43 |
84 Global pharmacoeconomics of Alzheimer's disease in light of potential cost effectiveness of disease modifying treatment
|
Wimo, Anders
|
|
2012
|
33 |
S1 |
p. S36-
1 p.
|
artikel
|
| 44 |
26 High-dose rivastigmine patch: results from the optima study
|
Frölich, Lutz
|
|
2012
|
33 |
S1 |
p. S12-
1 p.
|
artikel
|
| 45 |
6 How should we structure care for Alzheimer patients?
|
Bergman, Howard
|
|
2012
|
33 |
S1 |
p. S3-S4
2 p.
|
artikel
|
| 46 |
16 How similar and dissimilar are AD, PD, LBD and FTD?
|
Elble, Rodger J.
|
|
2012
|
33 |
S1 |
p. S8-
1 p.
|
artikel
|
| 47 |
57 Immunotherapy of protein aggregation diseases
|
Nitsch, Roger M.
|
|
2012
|
33 |
S1 |
p. S25-
1 p.
|
artikel
|
| 48 |
19 Importance of achieving optimal cholinesterase inhibitor dose
|
Farlow, Martin
|
|
2012
|
33 |
S1 |
p. S9-
1 p.
|
artikel
|
| 49 |
72 Influence of mid-life risk factors on late life cognitive and white matter changes: how should we time preventive interventions?
|
Skoog, Ingmar
|
|
2012
|
33 |
S1 |
p. S31-S32
2 p.
|
artikel
|
| 50 |
14 Inhibition of glutaminyl cyclase targeting neurodegeneration and neuroinflammation in Alzheimer's disease
|
Demuth, Hans-Ulrich
|
|
2012
|
33 |
S1 |
p. S7-
1 p.
|
artikel
|
| 51 |
10 Innovative therapeutic strategies for tau pathology: from cholesterol metabolism to immunotherapy
|
Buee, Luc
|
|
2012
|
33 |
S1 |
p. S5-
1 p.
|
artikel
|
| 52 |
81 In vivo tau imaging with PET
|
Villemagne, Victor L.
|
|
2012
|
33 |
S1 |
p. S35-
1 p.
|
artikel
|
| 53 |
41 Is tau phosphorylation the fuse and toxic Abeta the match?
|
Klein, William
|
|
2012
|
33 |
S1 |
p. S18-
1 p.
|
artikel
|
| 54 |
83 Ladostigil, a novel multifunctional drug for the prevention and treatment of Alzheimer's disease
|
Weinstock-Rosin, Marta
|
|
2012
|
33 |
S1 |
p. S36-
1 p.
|
artikel
|
| 55 |
9 Let's treat Alzheimer's disease - genetic aspects
|
Frisoni, G.B.
|
|
2012
|
33 |
S1 |
p. S4-S5
2 p.
|
artikel
|
| 56 |
24 Life course epidemiology in dementia - state of the art
|
Fratiglioni, Laura
|
|
2012
|
33 |
S1 |
p. S11-
1 p.
|
artikel
|
| 57 |
65 Management of neuropsychiatric symptoms in dementia
|
Robert, Philippe
|
|
2012
|
33 |
S1 |
p. S28-S29
2 p.
|
artikel
|
| 58 |
54 Mechanisms and treatment of Aβ-induced neuronal dysfunction
|
Mucke, Lennart
|
|
2012
|
33 |
S1 |
p. S24-
1 p.
|
artikel
|
| 59 |
77 Micro RNAs: a new therapeutic target in Alzheimer's disease
|
Soreq, Hermona
|
|
2012
|
33 |
S1 |
p. S33-S34
2 p.
|
artikel
|
| 60 |
25 MRI, hippocampal athropy and cognition
|
Frisoni, Giovanni B.
|
|
2012
|
33 |
S1 |
p. S11-S12
2 p.
|
artikel
|
| 61 |
23 MRI in the evaluation of therapeutic effects in clinical trials in early and presymptomatic AD
|
Fox, Nick
|
|
2012
|
33 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 62 |
12 NGF and Alzheimer's disease
|
Cuello, A. Claudio
|
|
2012
|
33 |
S1 |
p. S6-
1 p.
|
artikel
|
| 63 |
88 Non pharmacological intervention and caregiver support
|
Zanetti, Orazio
|
|
2012
|
33 |
S1 |
p. S38-
1 p.
|
artikel
|
| 64 |
33 Novel hypothesis-based Alzheimer's disease prediction biomarkers in blood and CSF
|
Hampel, Harald
|
|
2012
|
33 |
S1 |
p. S14-S15
2 p.
|
artikel
|
| 65 |
87 Novel new multi target anti Alzheimer drugs with neuroprotective and neurorestorative activities
|
Youdim, Moussa B.H.
|
|
2012
|
33 |
S1 |
p. S37-
1 p.
|
artikel
|
| 66 |
56 Novel phospho-tau specific liposome-based vaccines to treat tau pathology
|
Muhs, Andreas
|
|
2012
|
33 |
S1 |
p. S24-S25
2 p.
|
artikel
|
| 67 |
20 Novel programs in drug discovery for Alzheimer's disease
|
Fillit, Howard M.
|
|
2012
|
33 |
S1 |
p. S9-
1 p.
|
artikel
|
| 68 |
22 NPT002: a novel approach for targeting β-amyloid and tau aggregates in Alzheimer's disease
|
Fisher, Richard
|
|
2012
|
33 |
S1 |
p. S10-
1 p.
|
artikel
|
| 69 |
4 Optimal treatment for parkinson patients with cognitive disorders
|
Ballard, Clive
|
|
2012
|
33 |
S1 |
p. S2-S3
2 p.
|
artikel
|
| 70 |
73 Pharmacological rationale for cholinesterase inhibition in Alzheimer's disease
|
Small, Gary
|
|
2012
|
33 |
S1 |
p. S32-
1 p.
|
artikel
|
| 71 |
69 Preclinical and clinical considerations for abeta immunotherapy
|
Schenk, Dale
|
|
2012
|
33 |
S1 |
p. S30-
1 p.
|
artikel
|
| 72 |
75 Predict Alzheimer's disease tools for early diagnosis
|
Liu, Y.
|
|
2012
|
33 |
S1 |
p. S32-S33
2 p.
|
artikel
|
| 73 |
60 Prediction of dementia with simple clinical criteria in elderly subjects
|
Orgogozo, Jean-Marc
|
|
2012
|
33 |
S1 |
p. S26-
1 p.
|
artikel
|
| 74 |
40 Prevention of Alzheimer's disease, is it possible?
|
Kivipelto, Miia
|
|
2012
|
33 |
S1 |
p. S18-
1 p.
|
artikel
|
| 75 |
37 Promise and feasibility of inhibition of Tau's abnormal hyperphosphorylation
|
Iqbal, Khalid
|
|
2012
|
33 |
S1 |
p. S16-S17
2 p.
|
artikel
|
| 76 |
62 Relation of APOE to brain structure and function in Alzheimer's disease and aging
|
Pievani, Michela
|
|
2012
|
33 |
S1 |
p. S27-
1 p.
|
artikel
|
| 77 |
61 Repurposing anti-hypertensive drugs for Alzheimer's disease
|
Pasinetti, Giulio Maria
|
|
2012
|
33 |
S1 |
p. S26-S27
2 p.
|
artikel
|
| 78 |
48 Revamping the cholinergic system in Alzheimer's disease: Experience from stem cell studies
|
Wicklund, L.
|
|
2012
|
33 |
S1 |
p. S21-
1 p.
|
artikel
|
| 79 |
46 Reversibility of cognitive decline and synapse loss in regulatable mice with tau pathology
|
Mandelkow, Eva-Maria
|
|
2012
|
33 |
S1 |
p. S20-
1 p.
|
artikel
|
| 80 |
18 Small vessel disease
|
Erkinjuntti, Timo
|
|
2012
|
33 |
S1 |
p. S8-S9
2 p.
|
artikel
|
| 81 |
30 Taming beta-amyloid: Is that the solution?
|
Giacobini, Ezio
|
|
2012
|
33 |
S1 |
p. S13-S14
2 p.
|
artikel
|
| 82 |
78 Tauopathies: a single therapy for all?
|
Spillantini, Maria Grazia
|
|
2012
|
33 |
S1 |
p. S34-
1 p.
|
artikel
|
| 83 |
7 Testing new treatments with CSF biomarkers in early AD patients
|
Blennow, Kaj
|
|
2012
|
33 |
S1 |
p. S4-
1 p.
|
artikel
|
| 84 |
8 The brain of very old people: how does it work?
|
Bouras, Constantin
|
|
2012
|
33 |
S1 |
p. S4-
1 p.
|
artikel
|
| 85 |
28 The challenge of treating prodromal Alzheimer's disease patients
|
Gauthier, Serge
|
|
2012
|
33 |
S1 |
p. S12-S13
2 p.
|
artikel
|
| 86 |
42 The contribution of pet amyloid imaging to the study of drug effects
|
Klunk, William E.
|
|
2012
|
33 |
S1 |
p. S18-S19
2 p.
|
artikel
|
| 87 |
13 The relationship between cholinesterases and AD pathology
|
Darreh-Shori, Taher
|
|
2012
|
33 |
S1 |
p. S6-
1 p.
|
artikel
|
| 88 |
29 The safety and effectiveness of immune globulin intravenous (human), for the treatment of mild to moderate Alzheimer's disease
|
Gelmont, David
|
|
2012
|
33 |
S1 |
p. S13-
1 p.
|
artikel
|
| 89 |
2 The underlying mechanism of action of cholinesterase inhibitors and its implications for long-term Alzheimer's disease management
|
Andreasen, Niels
|
|
2012
|
33 |
S1 |
p. S1-S2
2 p.
|
artikel
|
| 90 |
15 Validation and implementation of the new diagnostic criteria for Alzheimer's disease
|
Dubois, Bruno
|
|
2012
|
33 |
S1 |
p. S7-
1 p.
|
artikel
|
| 91 |
79 What are genetic studies teaching us about how to treat Alzheimer's disease?
|
Tanzi, Rudolph
|
|
2012
|
33 |
S1 |
p. S34-
1 p.
|
artikel
|
| 92 |
1 What constitutes evidence of target engagement in AD trials? ELND005 CNS pharmacokinetics, biomarker, and safety profile
|
Lyketsos, C.
|
|
2012
|
33 |
S1 |
p. S1-
1 p.
|
artikel
|
| 93 |
43 Why have we failed to cure Alzheimer's disease?
|
Korczyn, Amos D.
|
|
2012
|
33 |
S1 |
p. S19-
1 p.
|
artikel
|
Tijdschrift beschrijving